Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 17/20 | 0.73 |
| ▸ | HTR2B | P41595 | 4/20 | 0.44 |
| ▸ | HTR2A | P28223 | 6/20 | 0.43 |
| ▸ | CCR3 | P51677 | 3/20 | 0.40 |
| ▸ | DRD2 | P14416 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5739640 | 1.00 | HTR2C (0.73) | HTR2CHTR2BHTR2ACCR3DRD2 | |
| SCHEMBL5739227 | 0.97 | HTR2C (0.78) | HTR2CHTR2BHTR2ACCR3DRD2 | |
| SCHEMBL5739232 | 0.97 | HTR2C (0.78) | HTR2CHTR2BHTR2ACCR3DRD2 | |
| SCHEMBL7229772 | 0.87 | HTR2C (0.94) | HTR2CHTR2BHTR2A | |
| SCHEMBL20698202 | 0.87 | HTR2C (0.94) | HTR2CHTR2BHTR2A | |
| SCHEMBL5394177 | 0.86 | HTR2C (0.92) | HTR2CHTR2BHTR2A | |
| SCHEMBL5633946 | 0.86 | HTR2C (0.92) | HTR2CHTR2BHTR2A | |
| SCHEMBL16168362 | 0.84 | HTR2C (1.00) | HTR2CHTR2BHTR2A | |
| SCHEMBL29434863 | 0.84 | HTR2C (1.00) | HTR2CHTR2BHTR2A | |
| SCHEMBL4354419 | 0.84 | HTR2C (1.00) | HTR2CHTR2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1497296-B1 | [1,4]DIAZOCINO[7,8,1-hi]INDOLE DERIVATIVES AS ANTIPSYCHOTIC AND ANTIOBESITY AGENTS | WYETH CORP (US) | 2006-03-22 | — | — | EP | claimed |
| US-7012089-B2 | [1,4]Diazocino[7,8,1-hi]indole derivatives as antipsychotic and antiobesity agents | WYETH (US) | 2006-03-14 | — | — | US | claimed |
| EP-1497296-B1 | [1,4]DIAZOCINO[7,8,1-hi]INDOLE DERIVATIVES AS ANTIPSYCHOTIC AND ANTIOBESITY AGENTS | WYETH CORP (US) | 2006-03-22 | — | — | EP | disclosed |
| US-7012089-B2 | [1,4]Diazocino[7,8,1-hi]indole derivatives as antipsychotic and antiobesity agents | WYETH (US) | 2006-03-14 | — | — | US | disclosed |
| EP-1497296-A1 | 1,4 DIAZOCINO 7,8,1-hi INDOLE DERIVATIVES AS ANTIPSYCHOTIC AND ANTIOBESITY AGENTS | Wyeth (US) | 2005-01-19 | — | — | EP | disclosed |
| US-20040034005-A1 | [1,4]Diazocino[7,8,1-hi]indole derivatives as antipsychotic and antiobesity agents | WYETH | 2004-02-19 | — | — | US | disclosed |
| WO-2003091257-A1 | [1,4]DIAZOCINO [7,8,1-hi]INDOLE DERIVATIVES AS ANTIPSYCHOTIC AND ANTIOBESITY AGENTS | WYETH (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034005-A1 | [1,4]Diazocino[7,8,1-hi]indole derivatives as antipsychotic and antiobesity agents | HTR1A, HTR2C, HTR1D | HTR2C 2/4885HTR2B 11/4885HTR2A 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.